Insight

The Efficacy and Safety of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer – Annals of Oncology

A. Alvarez Secord/dukecancerinstitute.org

Dec 3, 2024, 17:07

The Efficacy and Safety of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer – Annals of Oncology

Annals of Oncology shared a recent article by A. Alvarez Secord on X:

“New article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.”

Title: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

Authors: A. Alvarez Secord, S.N. Lewin, C.G. Murphy, S.C. Cecere, A. Barquín, F. Gálvez-Montosa, C.A. Mathews, G.E. Konecny, I. Ray-Coquard, A. Oaknin, M. J. Rubio Pérez, A. Bonaventura, E.J. Diver, S.-A. Ayuk, Y. Wang, B.R. Corr and V. Salutari

Mirvetuximab Soravtansine

More posts featuring Annals of Oncology.

A. Alvarez Secord A. Barquín Annals of Oncology B.R. Corr C.A. Mathews C.G. Murphy cancer E.J. Diver efficacy F. Gálvez-Montosa G.E. Konecny Mirvetuximab Soravtansine OncoDaily Oncology Ovarian Cancer PICCOLO Trial Platinum-Sensitive S.-A. Ayuk S.C. Cecere S.N. Lewin safety V. Salutari Y. Wang

New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in the NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial - JAMA Oncology

Monica Bertagnolli: 2024 Science Highlights from the NIH Director’s Blog

365 Days of OncoDaily: Ending 2024 Strong

Aladina Foundation was Honored with the Yvonne Humanitarian Award by OncoDaily

Rod Stewart and Prostate Cancer: How He Went Against, How He Survived, and More

Special Coverage